Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition

Stock Track

昨天

Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.

Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.

The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1147609075"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147609075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147609075?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147609075","market":"sg","top_or_hot":-1,"title":"Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition","media":"Stock Track","content":"<p>Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.</p><p>Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.</p><p>The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-12-24 18:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.</p><p>Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.</p><p>The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德納維製藥","start_time":0,"source_url":"","article_id":"1147609075","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147609075","pubTimestamp":1766572240,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.Sanofi will pay $15.50 per share in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药"},"translate_title":"个股追踪|赛诺菲同意22亿美元收购Dynavax盘前大涨37.56%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVAX":1},"content_text":"Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}